Galderma reported first-half 2024 net sales of $3.134 billion, up 24.6% year-over-year at constant currency, and raised its full-year guidance. The performance reflects robust demand for its toxin (Dysport, Azzalure) and filler (Restylane) portfolios, particularly in international markets.
Market
Galderma Raises Full-Year Guidance After Record First-Half Sales of $3.13B
Swiss aesthetics giant posts 24.6% YoY growth and lifts outlook, signaling strong demand across toxins and fillers despite market headwinds.
1-YEAR MOVE
ABBV▲11.6%EOLS▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
Galderma's 24.6% YoY growth and raised guidance suggest the injectables market is still expanding, not consolidating.
The upgrade is significant because Galderma is the only pure-play aesthetics company among the major toxin/filler manufacturers—AbbVie is pharma-diversified, Evolus is smaller and more volatile. Strong H1 results suggest the injectables market is not saturated despite price compression and increased competition from Hugel, Revance, and private-label toxins. Galderma's guidance lift typically signals confidence in Q3–Q4 volume and pricing power. For practices, this matters as a bellwether: if Galderma is growing at 24%+, the overall market is healthy, which usually means rebate programs remain competitive and supply chains stay stable.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.